Spektus, GEBRO Split Global Rights to ActraFlex Pain Drug
Image
Laval – November 03, 2026 -- Spektus Pharma and GEBRO Holding have agreed a global commercialization partnership for ActraFlex, a twice-daily extended-release tramadol/paracetamol formulation for pain management.
GEBRO takes Europe and Spektus takes the Americas under a split-territory deal
GEBRO, headquartered in Fieberbrunn, Austria, will lead commercialization and supply across Europe and selected international markets. The rollout is anchored by Spain, where GEBRO's Diliban brand has an established commercial presence.
Spektus, a Canadian specialty pharmaceutical company, will lead commercialization and supply across the Americas and selected markets in Africa and Asia. It will work through its network of regional pharmaceutical partners.
Each company will lead regulatory approvals in its own territories.